[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Vienna Hospital Association\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":131},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,44,74,99],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":27,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":4},"100649088","postoperative-cct-in-fecd-vs-non-fecd-100649088",false,"NCT07731945","Postoperative CCT in FECD vs. Non-FECD","Central Corneal Thickness After Cataract Surgery in Eyes With Fuchs Endothelial Corneal Dystrophy (FECD) Compared With Non-FECD Eyes: A Prospective, Controlled, Non-interventional Observational Clinical Study","Inclusion Criteria:\n\n1. Signed written informed consent for participation and for use of routine clinical data in pseudonymised form.\n2. Age ≥50 years at the time of cataract surgery.\n3. Scheduled cataract surgery (unilateral\u002Fbilateral cataract).\n4. No evidence of other ophthalmic diseases (e.g. macular pathology)\n\n   Cohort-specific inclusion:\n5. FECD cohort: Clinical diagnosis of FECD based on slit-lamp findings, graded accord-ing to Krachmer et al. (1978) as documented in routine care.\n6. Control cohort: No clinical evidence of corneal endothelial disease at baseline (no signs consistent with FECD or other endothelial pathology) as documented in routine care.\n\nExclusion Criteria:\n\n1. Corneal scars\n2. Pseudoexfoliation (PEX) syndrome\n3. Glaucoma\n4. Uveitis\n5. Diabetic retinopathy\n6. Other relevant ophthalmic disorders (e.g. retinal degeneration, macular or corneal pa-thologies)\n7. Previous intraocular surgery (including laser procedures)\n8. Ocular trauma (within the past 6 months)\n9. Pregnancy (if applicable, pregnancy must be excluded by a β-hCG test)\n10. CCT \\> 625μm",true,"ALL","50 Years",{"count":20,"type":21},98,"ESTIMATED","OBSERVATIONAL","This single-centre, prospective, controlled, non-interventional observational clinical study aims to characterize early postoperative corneal thickness behaviour after routine phacoemulsification cataract surgery in eyes with Fuchs endothelial corneal dystrophy (FECD) compared with non-FECD controls, using exclusively standard-of-care perioperative assessments. To compare central corneal thickness (CCT) six weeks postoperatively between FECD and non-FECD eyes, adjusting for baseline (preoperative) CCT.\n\nAll participants undergo routine phacoemulsification cataract surgery and routine perioperative assessments. Data are collected from the standard-of-care documentation at the following time points:\n\n1. Preoperative baseline visit (routine cataract work-up)\n2. Study specific postoperative follow-up at approximately 6 weeks. Each participant will attend a study-specific follow-up visit at 6 weeks postoperatively and contributes study-specific follow-up data up to this time point.\n\nThe routine clinical parameters assessed (as available per standard practice) include:\n\n(A) Medical history \u002F baseline characteristics and documentation of ocular\u002Fsystemic comorbidities and topical medication.\n\n(B) Best-corrected visual acuity (BCVA) (logMAR).\n\n(C) Intraocular pressure (IOP) measured by Goldmann applanation tonometry (GAT).\n\n(D) Slit-lamp examination (including assessment of corneal clarity\u002Fedema and anterior segment findings) with fundoscopy as routinely documented.\n\n(E) Central corneal thickness (CCT) measurement using routine clinical devices. All measurements will be performed at a consistent time of day for each patient.\n\n(F) Anterior segment optical coherence tomography (AS-OCT) using Casia2.\n\n(G) Anterior segment Scheimpflug tomography (Pentacam Oculus AXL).\n\n(H) Endothelial cell assessment or Endothelial Cell Count (ECC) examined with NIDEK® CEM-530 Specular Microscope:\n\n* Cell Density (CD) or Cell Count. Expressed as Cells\u002Fmm²\n* Coefficient of Variation (CV), represents the degree of variation in cell size (Polymegethism)\n* Percentage (%) of six-sided (hexagon) cells (HEX)\n* Standard Deviation (SD) of the average cell area.",[25,26],"Fuchs Endothelial Corneal Dystrophy","Cataract (Post-operative Cataract Surgery Follow-up)",[28,25,29,30,31],"Postoperative CCT","FECD","CCT in FECD","Cataract Surgery FECD","NOT_YET_RECRUITING","2026-08-05",{"date":35,"type":36},"2026-08-10","ACTUAL",{"date":38,"type":21},"2026-07-20",{"date":40,"type":21},"2027-08",{"name":42,"class":43},"Vienna Hospital Association","OTHER_GOV",{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":52,"targetDuration":54,"studyType":22,"phases":4,"briefSummary":55,"conditions":56,"keywords":59,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":73},"100648750","iol-power-formula-prediction-accuracy-at-the-extremes-of-axial-length-a-prospective-outcome-verification-study-100648750","NCT07724795","IOL Power Formula Prediction Accuracy at the Extremes of Axial Length: A Prospective Outcome Verification Study","Clinical Outcomes of Formula-dependent IOL Power Selection at the Extremes of Axial Length: a Cross-sectional Outcome Verification of Seven ESCRS-hosted Formulas and the Ladas Super Formula 2.0 in Short (\u003C22.0 mm) and Long (>26.0 mm) Eyes Using Refractive, Biometric, and Tomographic Assessment","FORMULEX-OV","Inclusion Criteria:\n\n* \\- Participation in the retrospective IOL power formula comparison study at the extremes of axial length (pseudonymized study ID assigned; complete preoperative biometry and archived formula outputs for all eight formula pathways)\n* Cataract surgery with a spherical (non-toric) IOL of one of the three reference models (HOYA Vivinex XY1, HOYA Vivinex Impress XY1-EM, or Johnson \\& Johnson Tecnis 1-Piece DIB00) at the study center between January 2022 and December 2025\n* Preoperative axial length below 22.0 mm (short stratum) or above 26.0 mm (long stratum), measured on IOLMaster 700\n* Documented implanted IOL model and power available from the operative record\n* At least 3 months since cataract surgery at the time of the outcome visit\n* Written informed consent for the outcome visit, including linkage of newly acquired postoperative data with the previously collected, pseudonymized preoperative planning data\n\nExclusion Criteria:\n\n* \\- Interval ocular surgery on the study eye since the original cataract surgery that may affect refraction or IOL position (e.g., corneal refractive surgery, IOL exchange or repositioning, secondary IOL implantation, or any intraocular surgery). Uncomplicated YAG laser capsulotomy without IOL repositioning is not an exclusion criterion\n* Implanted IOL not matching one of the three reference platforms (e.g., toric, multifocal or EDOF IOL, a different monofocal platform, or a sulcus-fixated IOL)\n* Toric IOL implantation\n* Acute ocular pathology preventing reliable refraction or biometric measurement\n* Cognitive or physical limitations precluding standardized subjective manifest refraction\n* Documented intraoperative complication with confirmed or suspected IOL malpositioning (e.g., posterior capsule rupture with vitreous loss, zonular dialysis requiring a capsular tension ring, sulcus placement)\n* Withdrawal of informed consent\n\nNote: macular pathology is not an exclusion criterion; macular status is documented on OCT and analyzed as a covariate.",{"count":53,"type":21},200,"6 Months","This single-center, prospective, cross-sectional study evaluates how accurately eight modern intraocular lens (IOL) power calculation formulas predicted the postoperative refractive result in eyes with extreme axial length after cataract surgery. Patients previously operated at the study center who had a very short (axial length \\\u003C 22.0 mm) or very long (\\> 26.0 mm) eye and received a spherical monofocal IOL are invited to a single, non-invasive outcome visit. At this visit, standardized manifest refraction, optical biometry, corneal tomography, slit-lamp examination and, in long eyes, macular OCT are performed. The measured postoperative spherical equivalent is compared with the residual refraction that each of the eight formulas had predicted for the actually implanted IOL power, separately in short and long eyes. The study aims to identify which formula predicts the postoperative outcome most accurately at the extremes of axial length, where formula choice is most consequential and least well studied.",[57,58],"Pseudophakia","Refractive Error",[60,61,62,63,64],"Intraocular lens power calculation","IOL formula","Axial length","Short eye","Long eye","2026-07-21",{"date":67,"type":36},"2026-07-24",{"date":69,"type":21},"2026-08-01",{"date":71,"type":21},"2027-07-01",{"name":42,"class":43},1,{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":78,"acronym":79,"eligibilityCriteria":80,"healthyVolunteers":11,"sex":17,"minAge":81,"maxAge":4,"enrollmentInfo":82,"targetDuration":4,"studyType":84,"phases":85,"briefSummary":87,"conditions":88,"keywords":90,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":95,"completionDateStruct":96,"leadSponsor":98,"locationsCount":73},"100646637","prospective-randomized-parallel-group-comparison-of-two-refractive-edof-intraocular-lenses-johnson--johnson-tecnis-puresee-versus-1stq-comfort-z-edof-100646637","NCT07688681","Prospective, Randomized, Parallel-group Comparison of Two Refractive EDOF Intraocular Lenses: Johnson & Johnson Tecnis PureSee Versus 1stQ Comfort Z-EDOF","1stQvsPureSee","Inclusion Criteria:\n\n* Age ≥40 years, able to understand the study and give written informed consent\n* Clinically significant bilateral age-related cataract suitable for phacoemulsification with posterior chamber IOL implantation\n* Expected postoperative best-corrected visual acuity ≤0.2 logMAR in both eyes\n* Regular corneal astigmatism ≤4.5 D in both eyes (IOLMaster 700)\n* Axial length 21.5-26.5 mm in both eyes\n* Clear cornea without clinically significant opacities, scars, or stromal dystrophies\n* Normal pupil function; no significant anisocoria (≥1 mm) and no afferent pupillary defect\n* Acceptance of the target refraction strategy: emmetropia in the dominant eye and -0.50 D in the non-dominant eye\n* Willing and able to attend all follow-up visits (Month 1, 3, and 6)\n* Written informed consent obtained before any study-related procedure\n\nExclusion Criteria:\n\n* Prior corneal refractive surgery, corneal transplantation, glaucoma filtering surgery, or vitreoretinal surgery in either eye (uncomplicated intravitreal injections allowed)\n* Irregular astigmatism, keratoconus, forme fruste keratoconus, corneal ectasia, significant corneal opacities or scars, or endothelial dystrophy\n* Keratometric astigmatism \\>4.5 D in either eye\n* Axial length \\\u003C21.5 mm or \\>26.5 mm in either eye\n* Calculated IOL power outside the available range of either study lens\n* Macular pathology expected to limit visual acuity (e.g., age-related macular degeneration, diabetic maculopathy, epiretinal membrane, macular hole)\n* Advanced glaucoma with central visual field involvement, or IOP not controlled on ≤2 topical medications\n* Optic neuropathy expected to limit visual potential\n* Pre-existing amblyopia in either eye\n* Significant anisocoria, afferent pupillary defect, non-dilating pupil, or iris abnormalities affecting IOL function or measurement\n* Endothelial cell density \\\u003C1500 cells\u002Fmm²\n* Uncontrolled diabetes mellitus (HbA1c \\>9%) or autoimmune disease with active ocular involvement\n* Systemic medications affecting pupil size that cannot be discontinued (e.g., tamsulosin)\n* Pregnancy or breastfeeding\n* Intraoperative complication precluding safe in-the-bag IOL implantation (affected eyes withdrawn)\n* Cognitive impairment, language barrier, or other factors preventing reliable participation\n* Current enrollment in another interventional clinical study affecting visual outcomes","40 Years",{"count":83,"type":21},110,"INTERVENTIONAL",[86],"NA","This study compares two types of artificial lens (intraocular lens, or IOL) used during cataract surgery. Both are extended depth-of-focus (EDOF) lenses, designed to give clear vision across a range of distances - far and intermediate - so that people depend less on glasses after surgery. The two lenses, the Tecnis PureSee and the 1stQ Comfort Z-EDOF, use different optical designs, and it is not yet known whether one provides a wider range of clear vision than the other.\n\nAdults having cataract surgery in both eyes may take part. Each participant is randomly assigned to receive one of the two lens types, and the same lens type is implanted in both eyes. Neither the participant nor the staff measuring vision knows which lens was used until the main 6-month assessment is complete.\n\nAfter surgery, participants attend check-ups at 1, 3, and 6 months. The study measures how wide a range of distances each person can see clearly, along with vision at different distances, quality of vision, side effects such as glare or halos, and overall satisfaction. The results will help doctors and patients choose between these lens types.",[89],"Cataract",[91],"EDOF intraocular lens","2026-06-30",{"date":94,"type":36},"2026-07-07",{"date":69,"type":21},{"date":97,"type":21},"2029-04-01",{"name":42,"class":43},{"id":100,"slug":101,"hasResults":11,"nctId":102,"briefTitle":103,"officialTitle":104,"acronym":105,"eligibilityCriteria":106,"healthyVolunteers":11,"sex":17,"minAge":107,"maxAge":108,"enrollmentInfo":109,"targetDuration":4,"studyType":84,"phases":111,"briefSummary":112,"conditions":113,"keywords":117,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":123,"lastUpdatePostDateStruct":124,"startDateStruct":126,"completionDateStruct":128,"leadSponsor":130,"locationsCount":73},"100628694","emg-and-delta-function-in-standard-rtsa-vs-lateralization-100628694","NCT07464977","EMG and Delta Function in Standard RTSA vs Lateralization","Postoperative Deltoid EMG Activity and Function in Patients After Reverse Total Shoulder Arthroplasty: A Comparison of Standard Implantation Technique and Lateralization","EMGRTSA","Inclusion Criteria:\n\n* male\u002Ffemale, 60-85y\n* diagnosis of Cuff tear arthropathy (CTA)\n* irreparable rotator cuff tear\n* severe osteoarthritis (OA)\n* primary RSA\n* verified rotator cuff tear in preoperative MRI\n* absence of severe cognitive impairment\n\nExclusion Criteria:\n\n* previous muscle transfer\n* revision surgery\n* highly dysplastic glenoid\n* axillary nerve palsy\n* upper limb radiculopathy\n* cervical myelopathy\n* degenerative muscular disease,\n* previous proximal humeral fracture\n* revision arthroplasty\n* rheumatoid arthritis","60 Years","85 Years",{"count":110,"type":21},130,[86],"Reverse total shoulder arthroplasty (RTSA) is a well-established method to treat patients with irreparable rotator cuff tears and glenohumeral osteoarthritis. The biomechanical principle implies a medialization and distalization of the center of rotation (COR). Deficiencies in internal and external rotation constitute frequently encountered functional problems. Some studies showed reduced activation of the posterior deltoid in EMG measurements, which may explain the inability to compensate these movements. Lateralized prosthetic designs demonstrated increased external rotation through an alteration of the deltoid's lever arm.\n\nThe aim of the study is to investigate the impact of lateralization on functional outcome and deltoid EMG activity in comparison to a standard implantation technique.",[114,115,116],"Cuff Tear Arthropathy","Omarthrosis","Rotator Cuff Tear Arthropathy",[118,119,120,121,122],"reverse total shoulder arthroplasty","cuff tear arthropathy","lateralization","deltoid function","EMG","2026-05-02",{"date":125,"type":36},"2026-05-07",{"date":127,"type":21},"2026-06",{"date":129,"type":21},"2027-12",{"name":42,"class":43},""]